What To Expect From Health Catalyst's (HCAT) Q1 Earnings
Stock Story
Published May 08, 2024 03:03AM ET
Updated May 08, 2024 08:04AM ET
What To Expect From Health Catalyst's (HCAT) Q1 Earnings
Healthcare software provider Health Catalyst (NASDAQ:HCAT) will be announcing earnings results tomorrow afternoon. Here's what to expect.
Health Catalyst beat analysts' revenue expectations by 2% last quarter, reporting revenues of $75.08 million, up 8.6% year on year. It was a weak quarter for the company, with management forecasting growth to slow and underwhelming revenue guidance for the next quarter.
Is Health Catalyst a buy or sell going into earnings? Find out by reading the original article on StockStory, it's free.
This quarter, analysts are expecting Health Catalyst's revenue to grow 1.3% year on year to $74.81 million, slowing from the 8.5% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.03 per share.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Health Catalyst has a history of exceeding Wall Street's expectations, beating revenue estimates every single time over the past two years by 1.9% on average.
Looking at Health Catalyst's peers in the data and analytics software segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Palantir (NYSE:PLTR) delivered year-on-year revenue growth of 20.8%, beating analysts' expectations by 2.7%, and Confluent reported revenues up 24.6%, topping estimates by 2.5%. Palantir traded down 15.1% following the results.
Read the full analysis of Palantir's and Confluent's results on StockStory.
Growth stocks have been quite volatile since the start of 2024, and while some of the data and analytics software stocks have fared somewhat better, they have not been spared, with share prices down 2.6% on average over the last month. Health Catalyst is up 1.4% during the same time and is heading into earnings with an average analyst price target of $11.9 (compared to the current share price of $6.77).
Get The News You Want
Written By: Stock Story
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.